Vertex Pharmaceuticals Incorporated (VRTX) Releases Earnings Results, Beats Expectations By $0.04 EPS

Vertex Pharmaceuticals Incorporated (VRTX) reported quarterly earnings results on Wednesday, Jul-27-2016. The company said it had a profit of $0.24 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.04. Analysts had a consensus of $0.20. The company posted revenue of $431.61 million in the period, compared to analysts expectations of $429.58 million. The company’s revenue was up 159.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.54 EPS.

Vertex Pharmaceuticals Incorporated opened for trading at $95.35 and hit $98.5 on the upside on Thursday, eventually ending the session at $96.21, with a gain of 0.21% or 0.2 points. The heightened volatility saw the trading volume jump to 14,55,192 shares. Company has a market cap of $23,798 M.

In a different news, on Jul 15, 2016, Joshua S Boger (director) sold 6,500 shares at $89.07 per share price. According to the SEC, on May 18, 2016, Amit Sachdev (EVP, Policy, Access & Value) sold 117 shares at $81.67 per share price. On May 18, 2016, Paul M Silva (SVP & Corp Controller) sold 202 shares at $82.06 per share price, according to the Form-4 filing with the securities and exchange commission.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Vertex Pharmaceuticals Incorporated

Leave a Reply

Vertex Pharmaceuticals Incorporated - Is it time to Sell?

Top Brokerage Firms are advising their investors on Vertex Pharmaceuticals Incorporated. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.